Mark Cuban's Cost Plus to Develop US-Made Ibogaine for HHS
Mark Cuban Cost Plus Drug Co. will lead research teams laying the groundwork for a domestically manufactured ibogaine product, part of a Department of Health and Human Services effort to develop the psychedelic as a potential treatment for post-traumatic stress disorder and other serious mental illnesses, according to Becker's Hospital Review. HHS committed up to $4.9 million to the work, with veterans a central focus.
Ibogaine, a psychoactive compound derived from the African iboga plant, is not approved in the US and carries known cardiac risks. The federal interest signals growing willingness to study psychedelics as options for conditions that respond poorly to existing drugs. Building a domestic supply chain also fits a broader government push to onshore pharmaceutical manufacturing.
For Cost Plus, known for low-cost generic drugs, the project expands its role into early-stage drug development alongside the federal government. Any approved product remains years away, but the funding marks a concrete step toward bringing a controversial therapy into regulated research.
Sources